Therapeutic Classification: antineoplastics
Pharmacologic Classification: anthracyclines, antimetabolites
High Alert
Daunorubicin
Absorption: IV administration results in complete bioavailability.
Distribution: Well distributed to tissues.
Half-Life: 31.5 hr.
Cytarabine
Absorption: IV administration results in complete availability.
Distribution: Well distributed to tissues.
Half-Life: 40.4 hr.
Contraindicated in:
Use Cautiously in:
CV: arrhythmias, chest pain, hypertension, hypotension, peripheral edema, CARDIOTOXICITY
Derm: petechiae, pruritus, rash
EENT: visual impairment, conjunctivitis, deafness, dry eye, eye edema
F and E: hyponatremia, hypokalemia
GI: abdominal pain, constipation, diarrhea, hemorrhoids, mucositis, nausea, vomiting, ↑liver enzymes, dyspepsia, hyperbilirubinemia
GU: renal impairment, ↓fertility (men)
Hemat: anemia, hemorrhage, neutropenia, thrombocytopenia
Local: phlebitis at IV site
MS: pain
Neuro: anxiety, delirium, dizziness, fatigue, headache, sleep disorders, hallucinations
Resp: cough, dyspnea, pleural effusion, RESPIRATORY FAILURE
Misc: chills, fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), INFECTION
Drug-drug:
This product is NOT interchangeable with other products containing daunorubicin or cytarabine.
Lab Test Considerations:
IV Administration:
Vyxeos has different dose recommendations than daunorubicin, cytarabine, and cytarabine liposome. It is not interchangeable with any of these products. Verify drug name and dose prior to preparation and administration to avoid dosing errors.